eFFECTOR Therapeutics to effect 1-for-25 reverse stock split on Jan 12, 2024

eFFECTOR Therapeutics, Inc.

Reverse stock split of 1-for-25 effective at 12:01 a.m. ET on Jan 12, 2024.
Outstanding shares reduce from approx. 74.9M to approx. 3.0M; authorized shares cut from 1B to 40M.
Par value unchanged; no fractional shares issued, cash paid for fractional interests.
Trading on Nasdaq on split-adjusted basis begins at market open Jan 12; new CUSIP 28202V207 for common.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

eFFECTOR Therapeutics, Inc.: Amendment to certificate of incorporation to effectuate a 1-for-25 reverse stock split, reducing authorized shares proportionally (effective 2024-01-12).

Change: charter amendment
Effective: 2024-01-12

Exact text from the filing

On January 9, 2024, eFFECTOR Therapeutics, Inc. (the “Company”) filed an amendment (the “Amendment”) to its amended and restated certificate of incorporation to effectuate a reverse stock split of the Company’s common stock, par value $0.0001per share (“Common Stock”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-24-005633

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.